Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hueber, A.
Right arrow Articles by Rech, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hueber, A.
Right arrow Articles by Rech, J
Haematologica, Vol 91, Issue 8_Suppl, ECR32-ECR32
Copyright © 2006 by Ferrata Storti Foundation

Case Reports

Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis

AJ Hueber, J Leipe, W Roesler, Kalden JR, S Kallert, and J Rech

Department of Internal Medicine III University of Erlangen - Nuremberg, Germany. axel.hueber@med3.imed.uni-erlangen.de

Polychemotherapy or radiation frequently causes oral mucositis. Until now, only supportive options are available. Palifermin, a recombinant form of the human keratinocyte growth factor can avoid mucositis in patients treated with myeloablative polychemotherapy for allogeneic stem cell transplantation. Here, we present a patient treated with dose-intense conventional polychemotherapy suffering from severe mucositis leading to additional hospitalization. By using palifermin, the mucositis as well as further admissions were totally prevented. Furthermore, application in subsequent chemotherapy cycles demonstrated a safe and efficacious use. Hence, treatment with palifermin can prevent severe mucositis in a patient treated with dose-intense conventional polychemotherapy.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.